Use of Oral Anticoagulant for Prevention of Embolic Stroke and Systemic Embolism in Atrial Fibrillation
Article Sidebar
Published:
Jun 1, 2018
Keywords:
Atrial fibrillation embolic stroke warfarin novel oral anticoagulants
Main Article Content
Abstract
Oral anticoagulant has the important role for prevention of embolic stroke and systemic embolism in patient with atrial fibrillation. Warfarin has been widely used as standard prophylactic medication for a long time. Currently, novel oral anticoagulants (NOACs) could demonstrate the evidence of good efficacy for prevention of embolic stroke with reduction of bleeding complication related with oral anticoagulant in atrial fibrillation
Article Details
How to Cite
Jirapattrathamrong, S. (2018). Use of Oral Anticoagulant for Prevention of Embolic Stroke and Systemic Embolism in Atrial Fibrillation. Vajira Medical Journal : Journal of Urban Medicine, 62(Supplement), S64–74. Retrieved from https://he02.tci-thaijo.org/index.php/VMED/article/view/209306
Section
Review Articles
References
1. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med 1995; 155(5):469-73.
2. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, et al. Prevalence of Diagnosed Atrial Fibrillation in Adults: National implications for rhythm management and stroke prevention: the AnTicoagulation & Risk Factors in Atrial Fibrillation (ATRIA) study. JAMA 2001; 285(18): 2370-5.
3. Miyasaka Y, Barnes ME, Gersch BJ, Bailey KR, Abhayaratna WP, et al. Secular Trends in Incidence of Atrial Fibrillation in Olmsted County, Minnesota, 1980 to 2000, and Implications on the Projections for Future Prevalence. Circulation 2006; 114(2):119-25.
4. Haim M, Hoshen M, Reges O, Rabi Y, Balicer R, Leibowitz M. Prospective national study of the prevalence, incidence, management and outcome of a large contemporary cohort of patients with incident non-valvular atrial fibrillation. J Am Heart Assoc 2015; 4(1):e001486.
5. Kiatchoosakun S PO, Chirawatkul A, Choprapawan C, Tatsanavivat P. Prevalence of cardiac arrhythmias in Thai community. J Med Assoc Thai 1999 Jul; 82(7):723-33.
6. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016;37:2893-962.
7. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke 1991;22:983-8.
8. ChienKL, SuTC, Hsu HC. Atrial fibrillation prevalence, incidence and risk of stroke and all-cause death among Chinese. Int J Cardiol 2010;139:173–80.
9. Gage BF, Waterman AD, Shannon W, Boechler M, RichMW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the national registry of atrial fibrillation. JAMA 2001;285:2864–70.
10. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor based approach: the euro heart survey on atrial fibrillation. Chest 2010;137:263–72.
11. Camm AJ, Lip GY, DeCaterina R.. Focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the American College of Cardiology. Eur Heart J 2012;2012(33):2719–47.
12. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, et al. AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation 2014;2014(130):2071–104.
13. Pisters R, Lane DA, Nieuwlaat R. A novel user-friendly score (HAS- BLED) To assess 1-year risk of major bleeding in patients with atrial fibrillation. Chest 2010;138:1093–100.
14. FribergL, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J 2012;33:1500–10.
15. Apostolakis S, Lane DA, GuoY. Performance of the HEMORR2HAGES, ATRIA, and HAS-BLED bleeding risk–prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (Evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) Study. J am Coll Cardiol 2012;60:861–7.
16. Hart RG,Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857–67.
17. Björck F, Renlund H, Lip GY, Wester P, Svensson PJ, Själander A. Outcomes in a Warfarin-Treated Population With Atrial Fibrillation. JAMA Cardiology 2016;1:172–80.
18. Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006;367:1903-12.
19. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51.
20. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al, ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883–91.
21. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al, ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981–92.
22. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al, Investigators EA-T. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369:2093–104.
23. Vadmann H, Nielsen PB, Hjortshoj SP, Riahi S, Rasmussen LH, Lip GY, Larsen TB. Atrial flutter and thromboembolic risk: a systematic review. Heart 2015;101:1446–55
24. Wellens HJ. Contemporary management of atrial flutter. Circulation 2002;106:649–52.
2. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, et al. Prevalence of Diagnosed Atrial Fibrillation in Adults: National implications for rhythm management and stroke prevention: the AnTicoagulation & Risk Factors in Atrial Fibrillation (ATRIA) study. JAMA 2001; 285(18): 2370-5.
3. Miyasaka Y, Barnes ME, Gersch BJ, Bailey KR, Abhayaratna WP, et al. Secular Trends in Incidence of Atrial Fibrillation in Olmsted County, Minnesota, 1980 to 2000, and Implications on the Projections for Future Prevalence. Circulation 2006; 114(2):119-25.
4. Haim M, Hoshen M, Reges O, Rabi Y, Balicer R, Leibowitz M. Prospective national study of the prevalence, incidence, management and outcome of a large contemporary cohort of patients with incident non-valvular atrial fibrillation. J Am Heart Assoc 2015; 4(1):e001486.
5. Kiatchoosakun S PO, Chirawatkul A, Choprapawan C, Tatsanavivat P. Prevalence of cardiac arrhythmias in Thai community. J Med Assoc Thai 1999 Jul; 82(7):723-33.
6. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016;37:2893-962.
7. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke 1991;22:983-8.
8. ChienKL, SuTC, Hsu HC. Atrial fibrillation prevalence, incidence and risk of stroke and all-cause death among Chinese. Int J Cardiol 2010;139:173–80.
9. Gage BF, Waterman AD, Shannon W, Boechler M, RichMW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the national registry of atrial fibrillation. JAMA 2001;285:2864–70.
10. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor based approach: the euro heart survey on atrial fibrillation. Chest 2010;137:263–72.
11. Camm AJ, Lip GY, DeCaterina R.. Focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the American College of Cardiology. Eur Heart J 2012;2012(33):2719–47.
12. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, et al. AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation 2014;2014(130):2071–104.
13. Pisters R, Lane DA, Nieuwlaat R. A novel user-friendly score (HAS- BLED) To assess 1-year risk of major bleeding in patients with atrial fibrillation. Chest 2010;138:1093–100.
14. FribergL, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J 2012;33:1500–10.
15. Apostolakis S, Lane DA, GuoY. Performance of the HEMORR2HAGES, ATRIA, and HAS-BLED bleeding risk–prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (Evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) Study. J am Coll Cardiol 2012;60:861–7.
16. Hart RG,Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857–67.
17. Björck F, Renlund H, Lip GY, Wester P, Svensson PJ, Själander A. Outcomes in a Warfarin-Treated Population With Atrial Fibrillation. JAMA Cardiology 2016;1:172–80.
18. Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006;367:1903-12.
19. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51.
20. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al, ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883–91.
21. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al, ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981–92.
22. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al, Investigators EA-T. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369:2093–104.
23. Vadmann H, Nielsen PB, Hjortshoj SP, Riahi S, Rasmussen LH, Lip GY, Larsen TB. Atrial flutter and thromboembolic risk: a systematic review. Heart 2015;101:1446–55
24. Wellens HJ. Contemporary management of atrial flutter. Circulation 2002;106:649–52.